Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 2, 2010, Pages 673-677

  Credito, Kim ^a   Kosowska Shick, Klaudia ^a   McGhee, Pamela ^a   Pankuch, Glenn A ^a   Appelbaum, Peter C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM MUTANT; CONTROLLED STUDY; NONHUMAN; PRESSURE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; DNA TOPOISOMERASES, TYPE II, BACTERIAL; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MUTATION; NAPHTHYRIDINES; OFLOXACIN; POLYMERASE CHAIN REACTION; QUINOLINES; STREPTOCOCCUS PNEUMONIAE;

EID: 75749090768     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01353-09     Document Type: Article

References (27)

1. Allen, G. P., G. W. Kaatz, and M. J. Rybak. 2003. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 47:2606-2614.
2. Andes, D., J. Anon, M. R. Jacobs, and W. A. Craig. 2004. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Clin. Lab. Med. 24:477-502.
3. Blondeau, J. M., L. D. Blondeau, C. Hesje, and S. Borsos. 2006. Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolones. J. Chemother. 18:366-372.
4. Blondeau, J. M., X. Zhao, G. Hansen, and K. Drlica. 2001. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:433-438.
5. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, seventh edition. Approved standard M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing. Approved standard M100-S19. Nineteenth informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Craig, W. A. 2001. The hidden impact of antibacterial resistance in respiratory tract infection. Re-evaluating current antibiotic therapy. Respir. Med. 95(Suppl. A):S12-S27.
8. de la Campa, A. G., C. Ardanuy, L. Balsalobre, E. Perez-Trallero, J. M. Marimon, A. Fenoll, and J. Linares. 2009. Changes in fluoroquinolone resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain. Emerg. Infect. Dis. 15:905-911.
9. Firsov, A. A., M. V. Smirnova, I. Y. Lubenko, S. N. Vostrov, Y. A. Portnoy, and S. H. Zinner. 2006. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J. Antimicrob. Chemother. 58:1185-1192.
10. Firsov, A. A., S. N. Vostrov, I. Y. Lubenko, K. Drlica, Y. A. Portnoy, and S. H. Zinner. 2003. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1604-1613.
11. Hansen, G. T., K. Metzler, K. Drlica, and J. M. Blondeau. 2003. Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47:440-441.
12. Hansen, G. T., X. Zhao, K. Drlica, and J. M. Blondeau. 2006. Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 27:120-124.
13. Hermsen, E. D., L. B. Hovde, G. N. Konstantinides, and J. C. Rotschafer. 2005. Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens. Antimicrob. Agents Chemother. 49:1633-1635.
14. Homma, T., T. Hori, G. Sugimori, and Y. Yamano. 2007. Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51:3810-3815.
15. Jacobs, M. R., S. Bajaksouzian, A. Zilles, G. Lin, G. A. Pankuch, and P. C. Appelbaum. 1999. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. surveillance study. Antimicrob. Agents Chemother. 43:1901-1908.
16. Jacobs, M. R., D. Felmingham, P. C. Appelbaum, and R. N. Gruneberg. 2003. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. 52:229-246.
17. Kosowska-Shick, K., K. Credito, G. A. Pankuch, G. Lin, B. Bozdogan, P. McGhee, B. Dewasse, D. R. Choi, J. M. Ryu, and P. C. Appelbaum. 2006. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents. Antimicrob. Agents Chemother. 50:2064-2071.
18. Li, X., X. Zhao, and K. Drlica. 2002. Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin. Antimicrob. Agents Chemother. 46:522-524.
19. MacGowan, A. P., C. A. Rogers, H. A. Holt, M. Wootton, and K. E. Bowker. 2001. Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection. Antimicrob. Agents Chemother. 45:2916-2921.
20. MacGowan, A. P., and R. Wise. 2001. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J. Antimicrob. Chemother. 48(Suppl. 1):17-28.
21. Pan, X. S., J. Ambler, S. Mehtar, and L. M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.
22. Schmidt, S., K. Rock, M. Sahre, O. Burkhardt, M. Brunner, M. T. Lobmeyer, and H. Derendorf. 2008. Effect of protein binding on the pharmacological activity of highly bound antibiotics. Antimicrob. Agents Chemother. 52:3994-4000.
23. Smith, H. J., M. Walters, T. Hisanaga, G. G. Zhanel, and D. J. Hoban. 2004. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates. Antimicrob. Agents Chemother. 48:3954-3958.
24. Stass, H., A. Dalhoff, D. Kubitza, and U. Schuhly. 1998. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob. Agents Chemother. 42:2060-2065.
25. Yamamoto, K., K. Yanagihara, K. Sugahara, Y. Imamura, M. Seki, K. Izumikawa, H. Kakeya, Y. Yamamoto, Y. Hirakata, S. Kamihira, and S. Kohno. 2009. In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms. Antimicrob. Agents Chemother. 53:3572-3575.
26. Zhao, X., and K. Drlica. 2002. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J. Infect. Dis. 185:561-565.
27. Zhao, X., W. Eisner, N. Perl-Rosenthal, B. Kreiswirth, and K. Drlica. 2003. Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1023-1027.